Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide…

Its that time again ... so, lets take a look at five pieces of content worth digging into deeper this…

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after…

Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the majority of…

On todays episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca…

Morningstar‘s US growth index is dominated by the “ Magnificent Seven.” But internationally, the scale is far smaller. There…

From pharma giants to sausage rolls, it was a day of upbeat numbers and market milestones. AstraZeneca soared, Barclays delivered…

CNBCs Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the companys most recent quarter, investment in innovation in…

TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.…

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was…

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca nach Zahlen auf "Hold" mit einem Kursziel…

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines…

AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand in the…

CAMBRIDGE (dpa-AFX) - Gute Geschäfte mit seinen Impfstoffen und Krebsmedikamenten haben den Pharmakonzern Astrazeneca im zweiten Quartal unerwartet viel…

AstraZeneca trumps Q2 forecasts, keeps outlook amid pricing, trade pressures…

AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but…

29 July 2025 AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and…

FTSE 100 dips negative Lloyds Bank and BT Group among fallers Rolls-Royce and AstraZeneca in positive ground US-EU deal better…

In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.…

It’s the most money the company has ever invested in a single manufacturing site.…